0001171843-16-010449.txt : 20160602 0001171843-16-010449.hdr.sgml : 20160602 20160602072222 ACCESSION NUMBER: 0001171843-16-010449 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20160602 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160602 DATE AS OF CHANGE: 20160602 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKORN INC CENTRAL INDEX KEY: 0000003116 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 720717400 STATE OF INCORPORATION: LA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32360 FILM NUMBER: 161691116 BUSINESS ADDRESS: STREET 1: 1925 W. FIELD COURT, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 BUSINESS PHONE: 847-279-6100 MAIL ADDRESS: STREET 1: 1925 W. FIELD COURT, SUITE 300 CITY: LAKE FOREST STATE: IL ZIP: 60045 8-K 1 f8k_060216.htm FORM 8-K
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________

Form 8-K
______________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 2, 2016  

Akorn, Inc.
(Exact Name of Registrant as Specified in Charter)

Louisiana001-3236072-0717400
(State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification Number)

 

1925 W. Field Court, Suite 300 , Lake Forest, Illinois 60045
(Address of Principal Executive Offices) (Zip Code)

(847) 279-6100
(Registrant's telephone number, including area code)


(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 [   ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 [   ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 [   ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 [   ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

Item 7.01. Regulation FD Disclosure.

On June 2, 2016, Akorn, Inc. issued a press release entitled “Akorn Updates Form S-8 Status by Filing Form 10-Q’s for First, Second and Third Quarters of 2015” Attached as Exhibit 99.1 and incorporated by reference into this Item 7.01 is a copy of the press release furnished as Exhibit 99.1 to this report.

The information in this Item 7.01, including exhibit 99.1 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.  See attached exhibit index.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 Akorn, Inc.
   
   
Date: June 2, 2016By: /s/ Duane A. Portwood        
  Name: Duane A. Portwood
  Title: Chief Financial Officer
  


EXHIBIT INDEX

 

Exhibit No. Description of Exhibit
   
99.1 Press release issued on June 2, 2016, by Akorn, Inc. entitled “Akorn Updates Form S-8 Status by Filing Form 10-Q’s for First, Second and Third Quarters of 2015.” 

 

 

 EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Akorn Updates Form S-8 Status by Filing Form 10-Q’s for First, Second and Third Quarters of 2015

LAKE FOREST, Ill., June 02, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015.  The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 that was filed with the SEC on May 10, 2016. The individual Forms 10-Q were filed solely in order to make effective the Company’s Registration Statement on Form S-8, on which the Company’s securities offered under its employee benefit plan are registered.

About Akorn, Inc. 
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Investors/Media:
Stephanie Carrington
ICR, Inc.
(646) 277-1282
Stephanie.carrington@icrinc.com